Mathematical Modeling of Alzheimer’s Drug Donepezil Hydrochloride Transport to the Brain after Oral Administration

Abstract

Alzheimer’s disease (AD) is a progressive degenerative disorder that causes behavioral changes, cognitive decline, and memory loss. Currently, AD is incurable, and the few available medicines may, at best, improve symptoms or slow down AD progression. One main challenge in drug delivery to the brain is the presence of the blood–brain barrier (BBB), a semi-permeable layer around cerebral capillaries controlling the influx of blood-borne particles into the brain. In this paper, a mathematical model of drug transport to the brain is proposed that incorporates two mechanisms of BBB crossing: transcytosis and diffusion. To account for the structural damage and accumulation of harmful waste in the brain caused by AD, the diffusion is assumed to be anomalous and is modeled using spatial Riemann–Liouville fractional-order derivatives. The model’s parameters are taken from published experimental observations of the delivery to mice brains of the orally administered AD drug donepezil hydrochloride. Numerical simulations suggest that drug delivery modalities should depend on the BBB fitness and anomalous diffusion and be tailored to AD severity. These results may inspire novel brain-targeted drug carriers for improved AD therapies.